Recruiting
Not applicable
Effect of LIMICOL®-NG on Plasma LDL-cholesterol Concentration in Subjects with Moderate Hypercholesterolemia
Condition(s) studied
Healthy Volunteer
Investigational drug(s) / intervention(s)
LIMICOL® NG
LIMICOL® NG: All subjects will consume 2 tablets per day during the entire intervention period, i.e. 12 weeks between V0 and V2, distributed as follows: 1 tablet in the morning at the end of or after breakfast (no taking on an empty stomach) and 1 tablet in the evening during dinner. If a dose is missed, 2 tablets can be taken at the next dose.
Study summary
The goal of this clinical trial is to observe a decrease in plasma LDL cholesterol concentration of 10% (or 0.20g/L) in subjects with untreated moderate hypercholesterolemia after 3 months of consumption of the Limicol®-NG food supplement, compared with a historical placebo group
Eligibility
Inclusion Criteria:
* For women
* If pre-menopausal: effective non-estrogenic contraception established for at least 2 cycles, to be maintained during the study,
* If menopausal: without estrogenic Hormone Replacement Therapy (HRT)
* LDL cholesterol \>1.3 g/L (according to Friedewald calculation);
* Having stable eating habits, a level of physical activity and a weight for at least 3 months before the start of the study;
* Agreeing to maintain their lifestyle habits throughout the duration of the study;
* Agreeing to follow the constraints generated by the study;
* Having signed the informed consent form;
* Social security insured.
Exclusion Criteria:
* Subjects receiving hypolipidemic or anti-dyslipidemic treatment (statin, ezetimibe, cholestyramine, fibrate, etc.)
* Subjects presenting triglyceridemia \> 4g/L (Friedewald)
* Subject requiring immediate treatment with statin
* Subject requiring immediate dietary intervention or having fluctuating eating behavior
* Diabetic subjects treated or not with medication
* Subjects with unstable treatment (for less than three months), or requiring the implementation of treatment during the study which, according to the investigator, could interfere with the evaluation of the study criteria (efficacy: LDL, TG, HDL, blood sugar, blood pressure, weight; safety: markers of liver, muscle or kidney function)
* Subjects who have consumed in the last 3 months food supplements or functional foods that could impact cholesterol or TG levels (phytosterol, phytostanol, red yeast rice, policosanols, beta-glucans at a dose greater than 3 g/day, probiotics)
* Subjects suffering from a severe chronic condition deemed incompatible with the study by the investigator (serious digestive pathologies, renal failure, coronary pathology, immunodeficiency, heart failure, rhythm disorders, progressive tumor pathology, blood disease)
* Subject suffering from a severe eating disorder (anorexia, bulimia, binge eating disorder)
* Pregnant woman or planning to become pregnant during the study period or breastfeeding
* Whose state of health or concomitant treatments are judged by the principal investigator or a qualified co-investigator to be incompatible with the proper conduct of the clinical study.
Primary outcome measure(s)
- Evolution over time (from 0 to 3 months) of the plasma concentration of LDL cholesterol — To baseline at 3 months
Historical placebo comparison of the evolution over time (from 0 to 3 months) of plasma LDL cholesterol concentration measured according to the Friedwald method (in g/L and %).
Trial sites (1)
| Facility | City | Region | Status |
|---|
| NutrInvest - Institut Pasteur de Lille |
Lille |
Nord |
Recruiting |
More Institut Pasteur de Lille trials in France
Other trials for the same condition
